Team NexTGen reveals a new T-cell subtype that uses MR1 to target cancer cells without harming healthy cells. This could transform immunotherapy and cancer vaccines. Read more in @jclinicalinvest: https://t.co/l3yqXfaH4I @CRUK@TheMarkFdn
Very happy with our latest publication in JCI published today 🥳 :
MHC-related protein 1–restricted recognition of cancer via a semi-invariant TCR-α chain https://t.co/LwzgGMIMRl
Thanks to children, young people & adults who met me & took part in this study. Without volunteers we can't do research to learn more about health- Thank you for taking part 👏 Here's our findings👇 @CTMUHB_RD@CUmedicengage@CUSystemsImmu@TcellResearch https://t.co/OGTWeKrapX
Thanks to the team for seeing our latest type 1 diabetes study over the line and published! 🏁 With special thanks to @DrLucyCJones and colleagues for rounding up the patient samples - we can’t do our research without their the generous participation! 🙏🏻
https://t.co/gmlhJk5saE
Don't miss the amazing Prof Andy Sewell (@TcellResearch) from @cardiffuni discussing his work on killer T cells in cancer survivors!
Have you registered yet? Earlybird closes Wednesday, get involved!🚨
Register👉 https://t.co/soNkLUxJz0
@bsicongress#TumourMicroenvironment24
Now online! Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy https://t.co/h93r1FG12E
🧵1 New research by Cardiff researchers discovers multipronged T-cells that “might be associated with complete cancer remission”.
💉 https://t.co/6Mcu02on94
Check out this presentation we gave of our recent work: new modes of cancer targeting by dissecting successful immunotherapy 🎉
Kindly hosted by @kidneycan 🙏🏻
#cancerimmunotherapy#tcells#immunology